These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 17923591

  • 1. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM.
    Arch Intern Med; 2007 Oct 08; 167(18):1930-6. PubMed ID: 17923591
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 08; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 08; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 4. A hard look at angiotensin receptor blockers in heart failure.
    Gring CN, Francis GS.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1841-6. PubMed ID: 15519017
    [Abstract] [Full Text] [Related]

  • 5. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.
    Kurnik D, Vesterman-Landes J, Bialik M, Katzir I, Lomnicky Y, Halkin H, Loebstein R.
    Clin Ther; 2011 Apr 02; 33(4):456-64. PubMed ID: 21635991
    [Abstract] [Full Text] [Related]

  • 6. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
    Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM.
    Circulation; 2004 Aug 10; 110(6):724-31. PubMed ID: 15289383
    [Abstract] [Full Text] [Related]

  • 7. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.
    Lakhdar R, Al-Mallah MH, Lanfear DE.
    J Card Fail; 2008 Apr 10; 14(3):181-8. PubMed ID: 18381180
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M, Tocci G, Sciarretta S, Verdecchia P, Trimarco B, Mancia G.
    J Hypertens; 2009 May 10; 27(5):941-6. PubMed ID: 19381108
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK, Duval S, Manske C, Vazquez G, Barber C, Miller L, Luepker RV.
    Am Heart J; 2007 Jun 10; 153(6):1064-73. PubMed ID: 17540211
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibitor and/or angiotensin receptor antagonist for the postmyocardial infarction patient.
    Scott RL.
    Cardiol Clin; 2008 Feb 10; 26(1):73-7, vii. PubMed ID: 18312907
    [Abstract] [Full Text] [Related]

  • 11. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan 10; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG.
    Arch Intern Med; 2006 Apr 10; 166(7):787-96. PubMed ID: 16606817
    [Abstract] [Full Text] [Related]

  • 13. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep 10; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials.
    Kang S, Yang Y, Li CJ, Gao R.
    Clin Ther; 2007 Nov 10; 29(11):2406-18. PubMed ID: 18158081
    [Abstract] [Full Text] [Related]

  • 15. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
    Krum H, Haas SJ, Eichhorn E, Ghali J, Gilbert E, Lechat P, Packer M, Roecker E, Verkenne P, Wedel H, Wikstrand J.
    Eur Heart J; 2005 Oct 10; 26(20):2154-8. PubMed ID: 16014644
    [Abstract] [Full Text] [Related]

  • 16. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Oct 10; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 17. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb 10; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 18. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
    de Denus S, Tardif JC, White M, Bourassa MG, Racine N, Levesque S, Ducharme A.
    Am Heart J; 2006 Oct 10; 152(4):705-12. PubMed ID: 16996842
    [Abstract] [Full Text] [Related]

  • 19. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
    J Clin Pharm Ther; 2005 Dec 10; 30(6):603-10. PubMed ID: 16336294
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J.
    Diabet Med; 2007 May 10; 24(5):486-93. PubMed ID: 17367311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.